8-K - MEDP - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2023

______________________________________________________

Medpace Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

______________________________________________________

Delaware	001-37856	32-0434904
(State or Other Jurisdiction<br>of Incorporation)	(Commission File Number)	(IRS Employer<br>Identification No.)
5375 Medpace Way
Cincinnati, Ohio		45227
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 513 579-9911

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br>Symbol(s)	Name of each exchange on which registered
Common Stock $0.01 par value	MEDP	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.07. Submission of Matters to a Vote of Security Holders.

(a) On May 19, 2023, Medpace Holdings, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders.

(b) Stockholders voted on the matters set forth below.

Proposal 1 - Election of Directors

The following nominees were elected to the Company’s Board of Directors to serve as Class I Directors until the Company’s 2026 Annual Meeting of Stockholders based upon the following votes:

	Votes<br>For	Votes<br>Withheld	Broker<br>Non-Votes
Brian T. Carley	15,744,076	12,066,720	1,172,784
Femida H. Gwadry-Sridhar	27,027,873	782,923	1,172,784
Robert O. Kraft	15,166,913	12,643,883	1,172,784

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based upon the following votes:

Votes <br>For	Votes<br>Against	Votes<br>Abstained	Broker <br>Non-Votes
28,343,821	630,701	9,058	0

Proposal 3 - Advisory Vote on the Compensation of our Named Executive Officers

The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved based upon the following votes:

Votes <br>For	Votes<br>Against	Votes<br>Abstained	Broker <br>Non-Votes
26,073,214	1,715,903	21,679	1,172,784

(d) Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MEDPACE HOLDINGS, INC.
Date:	May 19, 2023	By:	/s/ Stephen P. Ewald
		Name:	Stephen P. Ewald
		Title:	General Counsel and Corporate Secretary